Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)
Status:
Recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multi-center, double-blind, randomized, placebo-controlled study to
evaluate the safety and efficacy on TVB-2640 in subjects with non-alcoholic steatohepatitis
(NASH). Subjects will be randomly assigned toTVB-2640 or matching placebo PO QD for 52 weeks,
with the first dose administered on Day 1.